Details for Patent: 9,974,746

Which drugs does patent 9,974,746 protect, and when does it expire?

Patent 9,974,746 protects ANJESO and is included in one NDA.

This patent has sixteen patent family members in eight countries.

Summary for Patent: 9,974,746

Patent landscape, scope, and claims:

Title:	Reduction of flake-like aggregation in nanoparticulate active agent compositions
Abstract:	This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm.
Inventor(s):	Ryde; Niels P. (Malvern, PA), Snyder; Peter (King of Prussia, PA), Liu; Wei (Exton, PA), Slifer; David M. (Downingtown, PA)
Assignee:	Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:	15/130,255
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,974,746
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,974,746

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Baudax	ANJESO	meloxicam	SOLUTION;INTRAVENOUS	210583-001	Feb 20, 2020		DISCN	Yes	No			Y

International Family Members for US Patent 9,974,746

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010254180
Canada	2763456
European Patent Office	2435027
European Patent Office	3167875